Annual report
2784.TEDINET S100R438
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.70T | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥2.59T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥2.61T | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.70T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.64T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥30.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥29.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥32.8bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥32.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥31.9bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥57.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥55.1bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥38.6bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥48.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥32.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥24.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥40.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥41.7bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥32.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥1.34T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.30T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.32T | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.35T | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.34T | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥851.5bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥832.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥488.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥471.8bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥490.0bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥474.9bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥442.1bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥160.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥180.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥158.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥179.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥169.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥209.3bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥205.1bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥13.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥36.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥21.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥33.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥46.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥20.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥2.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.7bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.0bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥12.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥29.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥14.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥12.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥24.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥127.42 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥153.57 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.75 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥190.26 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.91 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,411.89 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,330.36 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,313.66 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,237.89 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,083.03 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.2% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.9% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.4% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 11,772 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 11,925 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 12,045 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 12,074 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 12,076 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥22.2bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥17.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥25.3bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥26.1bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥22.0bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥20.1bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥15.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥20.3bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥15.4bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥23.7bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥24.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥20.3bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥13.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥20.4bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥13.6bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥23.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥22.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥20.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥271.9bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥265.3bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥277.5bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥260.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥248.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥15.1bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥17.7bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥256.8bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥247.6bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥261.3bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥248.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥236.1bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥24.2bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥21.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥100.79 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.88 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥112.78 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.2 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥94.74 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥57 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥53 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,269.01 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,223.58 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,234.61 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,173.2 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,115.63 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 94.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.1% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 202,840,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 47 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 44 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 38 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 38 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 38 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 85
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥31.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥31.2bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥24.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | ¥315m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥8.5bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥6.2bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | employees | at 2023-03-31 | 8680 pure |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.40T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.38T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥16.8bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2023-03-31 | ¥1.14T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥27.0bn |
| Manufacturing Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Manufacturing Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥3.6bn |
| Manufacturing Businessreportable segment | employees | at 2023-03-31 | 1383 pure |
| Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥49.0bn |
| Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥35.2bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥13.9bn |
| Manufacturing Businessreportable segment | segment assets | at 2023-03-31 | ¥70.1bn |
| Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥420m |
| Medical Related Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥912m |
| Medical Related Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥396m |
| Medical Related Businessreportable segment | employees | at 2023-03-31 | 1187 pure |
| Medical Related Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥36.2bn |
| Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥36.2bn |
| Medical Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥0 |
| Medical Related Businessreportable segment | segment assets | at 2023-03-31 | ¥16.3bn |
| Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥330m |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥251m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥326m |
| Self Medication Products Wholesaling Businessreportable segment | employees | at 2023-03-31 | 398 pure |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥246.7bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥246.2bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥527m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2023-03-31 | ¥89.7bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥11.7bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥10.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥2.73T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥2.70T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥31.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.32T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥29.8bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥29.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥29.1bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥15.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | ¥332m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥6.0bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.29T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.27T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥15.7bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2022-03-31 | ¥1.12T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥24.8bn |
| Manufacturing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.9bn |
| Manufacturing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥3.3bn |
| Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥47.4bn |
| Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.6bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥12.8bn |
| Manufacturing Businessreportable segment | segment assets | at 2022-03-31 | ¥70.5bn |
| Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Medical Related Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥426m |
| Medical Related Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥387m |
| Medical Related Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥34.5bn |
| Medical Related Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.5bn |
| Medical Related Businessreportable segment | segment assets | at 2022-03-31 | ¥16.7bn |
| Medical Related Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥183m |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥306m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥357m |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥244.8bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥244.2bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥610m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2022-03-31 | ¥83.0bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥14.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥10.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥2.61T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥2.59T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥29.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥1.29T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥28.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,066
| Item | Context | Value | Unit |
|---|---|---|---|
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row4Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row4Member | Original text (Japanese)無(注)３ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row5Member | Original text (Japanese)㈱ツムラ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row5Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１・取引先持株会会員 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row5Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row6Member | Original text (Japanese)ロート製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row6Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１ ・株式分割 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row6Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row7Member | Original text (Japanese)久光製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row7Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１・取引先持株会会員 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row7Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row8Member | Original text (Japanese)持田製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row8Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row8Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row9Member | Original text (Japanese)ウエルシアホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row9Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１・取引先持株会会員 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row9Member | Original text (Japanese)無(注)３ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row10Member | Original text (Japanese)キッセイ薬品工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row10Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１・取引先持株会会員 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row10Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row11Member | Original text (Japanese)㈱メディカル一光グループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row11Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row11Member | Original text (Japanese)無(注)３ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row12Member | Original text (Japanese)ゼリア新薬工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row12Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row12Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row13Member | Original text (Japanese)キョーリン製薬ホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row13Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row13Member | Original text (Japanese)無(注)３ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row14Member | Original text (Japanese)明治ホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row14Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row14Member | Original text (Japanese)無(注)３ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row15Member | Original text (Japanese)スギホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row15Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row15Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row16Member | Original text (Japanese)科研製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row16Member | Original text (Japanese)・良好な財務取引の維持発展・当社グループの取引先 ・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row16Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row17Member | Original text (Japanese)あすか製薬ホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row17Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row17Member | Original text (Japanese)無(注)３ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row18Member | Original text (Japanese)㈱セブン＆アイ・ホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row18Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row18Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row19Member | Original text (Japanese)㈱ほくやく・竹山ホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row19Member | Original text (Japanese)・同業界内における関係維持発展に伴う中 長期的な企業価値の向上・当社グループの取引先・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row19Member | Original text (Japanese)無(注)３ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row20Member | Original text (Japanese)ミアヘルサホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row20Member | Original text (Japanese)・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row20Member | Original text (Japanese)無 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |